checkAd

     290  0 Kommentare Bavarian Nordic to Host First Quarter 2017 Results Conference Call

    COPENHAGEN, Denmark - April 27, 2017 - Bavarian Nordic A/S (OMX:  BAVA, OTC: BVNRY) will announce its 2017 first quarter results on Thursday, May 4, 2017.

    The management of Bavarian Nordic will host a conference call at 2:00 pm CEST (8:00 am EDT) on the same day to present the interim results followed by a Q&A session.

    Dial-in numbers for the conference call are: Denmark: +45 32 71 16 60, UK: +44 (0) 20 3427 1911, USA: +1 646 254 3364. Participant code is 7659153.

    A live and archived webcast of the call and relevant slides will be available at http://bit.ly/2popqvJ.

    Contacts
    Europe: Rolf Sass Sørensen, Vice President Investor Relations & Communications. Phone +45 61 77 47 43
    U.S.: Seth Lewis, Vice President, Investor Relations & Communications. Phone: +1 978 341 5271

    About Bavarian Nordic
    Bavarian Nordic is a fully integrated biotechnology company focused on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases, based on the Company's live virus vaccine platform. Through long-standing collaborations, including a collaboration with the U.S. government, Bavarian Nordic has developed a portfolio of vaccines for infectious diseases, including the non-replicating smallpox vaccine, IMVAMUNE®, which is stockpiled for emergency use by the United States and other governments. The vaccine is approved in the European Union (under the trade name IMVANEX®) and in Canada. Bavarian Nordic and its partner Janssen are developing an Ebola vaccine regimen, which has been fast-tracked, with the backing of worldwide health authorities, and a vaccine for the prevention and treatment of HPV. Additionally, in collaboration with the National Cancer Institute, Bavarian Nordic has developed a portfolio of active cancer immunotherapies, including PROSTVAC®, which is currently in Phase 3 clinical development for the treatment of advanced prostate cancer. The company has partnered with Bristol-Myers Squibb for the potential commercialization of PROSTVAC. For more information visit www.bavarian-nordic.com or follow us on Twitter @bavariannordic.




    This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
    The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
    Source: Bavarian Nordic A/S via Globenewswire



    Diskutieren Sie über die enthaltenen Werte


    GlobeNewswire
    0 Follower
    Autor folgen

    Verfasst von GlobeNewswire
    Bavarian Nordic to Host First Quarter 2017 Results Conference Call COPENHAGEN, Denmark - April 27, 2017 - Bavarian Nordic A/S (OMX:  BAVA, OTC: BVNRY) will announce its 2017 first quarter results on Thursday, May 4, 2017. The management of Bavarian Nordic will host a conference call at 2:00 pm CEST (8:00 am EDT) …

    Schreibe Deinen Kommentar

    Disclaimer